- P-ISSN 1010-0695
- E-ISSN 2288-3339
Objectives: Yongdamsagan-tang (YST) and Paljung-san (PJS) in traditional medicine and finasteride in modern medicine are used to treat benign prostatic hyperplasia (BPH). In recent, the use of combination herbal remedies with conventional drugs has been increasing. Therefore, we investigated the anti-inflammatory effects of these drugs to treat BPH and the influence of herbal formulas on finasteride metabolism. Methods: The inhibitory effects of the herbal formulas and finasteride on the production of inflammatory mediators and cytokines were determined in lipopolysaccharide (LPS)-treated RAW 264.7 cells. Additionally, the influence of herbal formulas on activities of human drug metabolizing enzymes (DMEs) was assessed using human microsomal enzymes. Results: We observed that YST, PJS and finasteride inhibited the production of nitric oxide (NO), prostaglandin E2 (PGE2) and interleukin-6 (IL-6) in RAW 264.7 cells. The half maximal inhibitory concentration (IC50) of YST on PGE2 production was calculated to be below 25 μg/mL. YST inhibited the activity of uridine diphosphate- glucuronosyltransterase (UGT) 1A4 with an IC50 value of 49.35 μg/mL. The activities of cytochrome P450 (CYP) 1A2, CYP2B6, CYP2C19, CYP3A4, and UGT1A1 were inhibited by PJS (IC50 < 100 μg/mL, each). Although PJS and YST inhibited the activities of CYP3A4 and UGT1A4, respectively, these formulas may not influence the metabolism of finasteride because the IC50 values of herbal formulas on DMEs are too high to affect metabolism. Conclusions: Our results suggest that the combination of finasteride and YST or PJS might not influence their drug metabolism and that the drugs may have synergistic effects against BPH.
1. Brasure, M., MacDonald, R., Dahm, P., Olson, C. M., Nelson, V. A., Fink, H. A., et al. (2016). Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Review. Rockville (MD): Agency for Healthcare Research and Quality (US). http://www.ncbi.nlm.nih.gov/books/NBK368444/
2. Elkelany, O. O., Owen, R. C., & Kim, E. D. (2015). Combination of tadalafil and finasteride for improving the symptoms of benign prostatic hyperplasia: critical appraisal and patient focus. Therapeutics and Clinical Risk Management, 11, 507-513. https://doi.org/10. 2147/TCRM.S80353
3. Azimi, H., Khakshur, A. A., Aghdasi, I., Fallah-Tafti, M., & Abdollahi, M. (2012). A review of animal and human studies for management of benign prostatic hyperplasia with natural products: perspective of new pharmacological agents. Inflammation and Allergy Drug Targets, 11(3), 207-221. https://doi.org/10.2174/187152812800392715
4. Yuan, H., Ma, Q., Ye, L., & Piao. G. (2016). The traditional medicine and modern medicine from natural products. Molecules, 21(5): 559. https://doi.org/10.3390/molecules21050559
5. Chen, J., Li, P., Sun, Z., Wang, C., Wang, T., & Wang, B. (2015). Five methods of syndrome differentiation and treatment for benign prostatic hyperplasia. Journal of Practical Traditional Chinese Internal Medicine, 29(11), 67-69. https://doi.org/10.13729/j.issn. 1671-7813.2015.11.32
6. Lee, T. Y. & Chang, H. H. (2010). Longdan Xiegan Tang has immunomodulatory effects on CD4+CD25+ T cells and attenuates pathological signs in MRL/lpr mice. International Journal of Molecular Medicine, 25(5), 677-85. https://doi.org/10.3892/ijmm_00000391
7. Kim, J. J., Kim, H. J., An, B. K., Hong, W. S., Kim, W. H., Lee, S. I., et al. (1978). Studies on the therapeutics for liver diseases in herb remedies (VI): Experimental study on the effect on Ryongdamsakan-Tang. Kyung Hee University Oriental Medical Journal, 1, 31-5.
8. Seo, M. S., Jin, Y. S., & Jung, K. M. (1991). Effects of Yongdamsagantang and Yongdamsagantang -gamibang on the anti-allergic effect in rats and mice. Journal of Korean Oriental Pediatrics, 5, 15-27. https://www.koreascience.or.kr/article/JAKO199104637300724.pdf
9. Furuya, S. & Takahashi, K. (2003). Clinincal investigation of the efficacy of Ryutan-shakan -to in the treatment of postoperative pain and discomfort following transurethral resection of the prostate. Kampo Medicine, 54(1), 183-189. https://www.jstage.jst.go.jp/article/kampomed 1982/54/1/54_1_183/_pdf/-char/ja
10. Moriyama, M. T., Ikeda, R., & Suzuki, K. (2003). Ryutan-shakan-to for the treatment of urination difficulty. Journal of Traditional Medicine, 20(5), 230-234.
11. Song, M. K., Park, S. H., Kang, J. S., Ahn, Y. M., Ahn, S. Y., Kim, Y. O., et al. (2010). Report of four cases of Paljung-san on lower urinary tract symptoms in patients with benign prostatic hyperplasia. Journal of Korean Oriental Medicine, 31(1), 153-161. https://www.koreascience.or.kr/article/JAKO201021147394355.pdf
12. Lee, S. W., Na, H. Y., Yoo, J. H., Ahn, Y. M., Ahn, S. Y., Kin, Y. O., et al. (2015). Effects of Paljeong-san on chronic nonbacterial prostatitis induced in rats by estradiol. Journal of Internal Korean Medicine, 36(2), 180-188. https://www.koreascience.or.kr/article/JAKO201525850332466.pdf
13. Tong, Y. & Zhou, R. Y. (2020). Review of the roles and interaction of androgen and inflammation in benign prostatic hyperplasia. Mediators of Inflammation, 2020:7958316. https://doi.org/10.1155/2020/7958316
14. Krušlin, B., Tomas, D., Džombeta, T., Milković-Periša, M., & Ulamec, M. (2017). Inflammation in prostatic hyperplasia and carcinoma-basic scientific approach. Frontiers in Oncology, 7, 77. https://doi.org/10.3389/fonc.2017.00077
15. Park, E., Lee, M. Y., Jeon, W. Y., Lee, N., Seo, C. S., & Shin, H. K. (2016). Inhibitory effect of Yongdamsagan-Tang water extract, a traditional herbal formula, on testosterone -induced benign prostatic hyperplasia in rats. Evidence Based Complement and Alternative Medicine, 2016, 1428923. https://doi.org/10.1155/2016/1428923
16. Park, E., Lee, M. Y., Seo, C. S., Jeon, W. Y., & Shin, H. K. (2017). Yongdamsagan-tang, a traditional herbal formula, inhibits cell growth through the suppression of proliferation and inflammation in benign prostatic hyperplasia epithelial-1 cells. Journal of Ethnopharmacology, 209, 230-235. https://doi.org/10.1016/j.jep.2017. 08.002
17. Park, E., Lee, M. Y., Jeon, W. Y., Seo, C. S., You, S., & Shin, H. K. (2018). Paljung-San, a traditional herbal medicine, attenuates benign prostatic hyperplasia in vitro and in vivo. Journal of Ethnopharmacology, 218, 109-115. https://doi.org/10.1016/j.jep.2018.02.037
18. Agbabiaka, T. B., Wider, B., Watson, L. K., & Goodman, C. (2017). Concurrent use of prescription drugs and herbal medicinal products in older adults: A systematic review. Drugs Aging, 34, 891–905. https://doi.org/10.1007/s40266-017-0501-7
19. Amitani, M., Amitani, H., Sloan, R. A., Suzuki, H., Sameshima, N., Asakawa, A., et al. (2015). The translational aspect of complementary and alternative medicine for cancer with particular emphasis on Kampo. Frontiers in Pharmacology, 6, 150. https://doi.org/10.3389/fphar.2015.00150
20. Vuichoud, C. & Loughlin, K. R. (2015). Benign prostatic hyperplasia: epidemiology, economics and evaluation. The Canadian Journal of Urology, 22(Suppl 1), 1-6. https://www.canjurol.com/html/free-articles/J UV22I5S1F_06_DrLoughlin.pdf
21. Olesovsky, C. & Kapoor, A. (2016). Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia. Therapeutic Advances in Urology, 8(4), 257-271. https://doi.org/10.1177/1756287216650132
22. Kim, E. H., Larson, J. A., & Andriole, G. L. (2016). Management of Benign Prostatic Hyperplasia. Annual Review of Medicine, 67, 137-151. https://doi.org/10.1146/annurev -med-063014-123902
23. Di Silverio, F., Bosman, C., Salvatori, M., Albanesi, L., Proietti Pannunzi, L., Ciccariello, M., et al. (2005). Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). European Urology, 47(1), 72-79. https://doi.org/10.1016/j.eururo.2004.08.024
24. Kramer, G., Mitteregger, D., & Marberger, M. (2007). Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? European Urology, 51(5), 1202-1216. https://doi.org/10.1016/j.eururo.2006.12.011
25. Ma, C. H., Lin, W. L., Lui, S. L., Cai, X. Y., Wong, V. T., Ziea, E., et al. (2013). Efficacy and safety of Chinese herbal medicine for benign prostatic hyperplasia: systemic review of randomized controlled trials. Asian Journal of Andrology, 15(4), 471-482. https://doi.org/10.1038/aja.2012.173
26. Lim, J. H., Lee, J. R., Kim, S. C., & Jee, S. Y. (2007). Inhibitory effect of Yongdamsagantang water extract in IL-6 and nitric oxide production in lipopolysaccharide-activated RAW264.7 cells. Oriental Pharmacy and Experimental Medicine, 7(3), 321-329. https://doi.org/10.3742/OPEM.2007.7.3.321
27. Williams, J. A., Hyland, R., Jones, B. C., Smith, D. A., Hurst, S., Goosen, T.C., et al. (2004). Drug-drug interactions for UDP -glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metabolism and Disposition, 32(11), 1201-1208. https://doi.org/10.1124/dmd.104.000794
28. Huang, S. M. & Lesko, L.J. (2004). Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food interactions: what have we learned? Journal of Clinical Pharmacology, 44(6), 559-569. https://doi.org/10.1177/0091270004265367
29. Prueksaritanont, T., Chu, X., Gibson, C., Cui, D., Yee, K. L., Ballard, J., et al. (2013). Drug-drug interaction studies: regulatory guidance and an industry perspective. The AAPS Journal, 15(3), 629-645. https://doi.org/10.1208/s12248-013-9470-x
30. Grimstein, M. & Huang, S.M. (2018). A regulatory science viewpoint on botanical-drug interactions. Journal of Food and Drug Analysis, 26(2S), S12-S25. https://doi.org/10.1016/j.jfda.2018.01.013
31. Hulin-Curtis, S. L., Petit, D., Figg, W. D., Hsing, A. W., & Reichardt, J. K. (2010). Finasteride metabolism and pharmacogenetics:new approaches to personalized prevention of prostate cancer. Future Oncology, 6(12), 1897-1913. https://doi.org/10.2217/fon.10.149